RecruitingNCT04592523
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea
Sponsor
Takeda
Enrollment
257 participants
Start Date
Sep 5, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
Eligibility
Min Age: 19 Years
Inclusion Criteria2
- With ALK-positive advanced or metastatic NSCLC.
- Who initiate brigatinib for the first time.
Exclusion Criteria3
- Treated with brigatinib outside of the locally approved label in Korea.
- Whom brigatinib is contraindicated as per product label.
- Participating in other clinical trials of NSCLC treatment.
Interventions
OTHERNo Intervention
This is a non-interventional study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04592523
Related Trials
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT0416579847 locations
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT0416507046 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632154 locations
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
NCT044990534 locations
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310337 locations